Effect of hepatitis B x gene on the expression of major histocompatibility complex class I chain-related gene A-A5. 1,invasion,and migration of HepG2. 2. 15 cells

Abstract

Objective To investigate the effect of hepatitis B x( HBx) gene on the expression of major histocompatibility complex class I chain-related gene A( MICA)-A5. 1,invasion,and migration of HepG2. 2. 15 cells. Methods HepG2. 2. 15 cells( HepG2 cells with the insertion and continuous expression of whole HBV genome) were cultured in vitro and were randomly divided into control group,HBx overexpression plasmid group,HBx empty plasmid group,HBx siRNA group,and HBx siRNA negative control group. After the transfection of plasmid or siRNA,CCK-8 assay was used to measure cell proliferation after 24 and 48 hours to screen out the appropriate duration of drug action; the Transwell invasion test and wound-healing assay were used to observe the changes in cell invasion and migration abilities;immunoblotting was used to measure the expression of HBx,MICA-A5. 1,and the marker proteins for epithelial-mesenchymal transition E-cadherin and vimentin; ELISA was used to measure the level of soluble MICA( s MICA) in cell culture medium. A one-way analysis of variance was used for comparison of continuous data between multiple groups,and the SNK q test was used for further comparison between two groups. Results Compared with the control group after 24 hours,the HBx overexpression plasmid group had a significant increase in cell viability and the HBx siRNA group had a significant reduction in cell viability( q = 8. 268 and 4. 365,P < 0. 001 and 0. 036); compared with the control group after 48 hours,the HBx overexpression plasmid group had a significant increase in cell viability and the HBx siRNA group had a significant reduction in cell viability( q = 12. 680 and 7. 523,both P < 0. 001). Compared with the control group,the HBx overexpression plasmid group had significant increases in the protein expression of HBx,MICA,and vimentin in cells,the level of s MICA in cell culture medium,the number of migrating cells,and the number of cells out of the Transwell chamber,as well as a significant reduction in the expression of E-cadherin( q = 9. 427,6. 697,10. 500,5. 042,22. 740,15. 720,and 5. 258,all P < 0. 05); the HBx siRNA group had significant reductions in the protein expression of HBx,MICA,and vimentin in cells,the level of s MICA in cell culture medium,the number of migrating cells,and the number of cells out of the Transwell chamber,as well as a significant increase in the expression of E-cadherin( q = 8. 133,8. 828,7. 616,7. 673,5. 391,7. 694,and 6. 226,all P < 0. 05). Conclusion The HBx gene regulates theexpression of MICA-A5. 1 in HepG2. 2. 15 cells and the invasion and migration of HepG2. 2. 15 cells,and upregulation of the HBx gene can promote the expression of MICA-A5. 1 and enhance the invasion and migration abilities of HepG2. 2. 15 cells.
- hepatitis B virus,
- Hep G2 cells,
- genes,MHC classⅠ

FullText(HTML)

目前我国慢性HBV感染者约0.7亿人，其中慢性乙型肝炎(CHB)患者为0.2亿~0.3亿例^[1]。自1998年第一个核苷(酸)类似物(NAs)抗HBV药物拉米夫定(LAM)在我国临床应用至今，先后有阿德福韦酯(ADV)、替比夫定(LdT)、恩替卡韦(ETV)、替诺福韦酯(TDF)和丙酚替诺福韦(TAF)陆续应用于临床。作为逆转录酶抑制剂，NAs可强效抑制HBV复制，目前临床接受抗病毒治疗的患者中约80%应用NAs治疗^[2]。但由于单纯的NAs治疗难以获得持久的免疫学应答，HBsAg阴转率仅0~3%，停药后容易复发，需要长期甚至终身服药。因此如何进一步提高NAs经治患者的疗效并尽可能实现临床治愈是临床亟待解决的热点和难点问题^[2-4]。本研究选取NAs经治HBeAg阴性CHB低水平HBsAg患者进行临床研究，探讨如何选取优势人群和应用更短疗程获得CHB临床治愈的方法。

1. 资料与方法

1.1 研究对象

选取2017年10月—2019年10月在鹤壁市第三人民医院接受治疗的CHB患者。入组标准：诊断均符合《慢性乙型肝炎防治指南(2015年更新版)》^[5]中的诊断标准。NAs治疗均48周以上，入组时HBeAg阴性，HBsAg精准定量检测＜1500 IU/ml，HBV DNA＜200 IU/ml。排除标准：重叠或混合甲、丙、丁、戊等其他类型病毒感染者；有肝硬化或其他严重器质性病变的患者；妊娠或哺乳期妇女；精神异常者等。

1.2 研究方法

根据患者意愿，分为联合治疗组(A组)和NAs单药治疗组(B组)。A组，在NAs治疗基础上联合聚乙二醇干扰素(PEG-IFN)α-2b(厦门特宝生物工程股份有限公司，国药准字S20160001) 进行治疗，用药方式为皮下注射，180 μg/次，1次/周，联合治疗48周。联合治疗期间获得HBsAg阴转、抗-HBs＞100 IU/ml，满足联合治疗24周，可考虑停用联合治疗方案，并观察至48周，否则继续联合治疗至48周。B组，NAs单药治疗，观察48周。观察记录所有入组患者12、24、36、48周乙型肝炎五项精准定量结果、生化学指标和用药的不良反应。乙型肝炎五项精准定量检测采用美国雅培全自动化学发光分析仪微粒子酶免疫化学发光法；高灵敏度HBV DNA的检测使用COBASAmpliPrep/COBASTaqMan分析仪，检测下限：0~20 IU/ml。

1.3 观察指标及评价标准

观察两组乙型肝炎五项血清学指标动态变化。主要指标：HBsAg阴转率和抗-HBs阳转率。判定标准：HBsAg＜0.05 IU/ml视为阴性，抗-HBs＞10 IU/ml视为HBsAg血清学转换。抗-HBs＞100 IU/ml，视为稳定阈值^[6]。

1.4 伦理学审查

本研究获得鹤壁市第三人民医院伦理委员会批准，批号：论研批第2017-RS001。纳入患者均签署知情同意书。

1.5 统计学方法

采用SPSS 17.0统计学软件进行数据分析。计量资料以x±s表示，两组间比较采用t检验；计数资料组间比较采用Fisher精确检验。影响因素相关分析采用logistic回归法。P＜0.05为差异有统计学意义。

2. 结果

2.1 一般资料

选取接受治疗的CHB患者44例，其中男36例，女8例，年龄(47.51±7.21)岁。排除1例患者在应用NAs联合PEG-IFN治疗4周后癫痫发作而停药；另1例患者联合治疗6周后因白细胞及血小板过低而停药，共42例患者完成规定疗程进入本研究，其中A组22例，B组20例。A组中接受ETV治疗18例、LAM 1例、ADV 3例，疗程1~14(5.8±3.99)年。B组中接受LAM治疗1例、LAM+ADV 1例、TDF 1例、ETV 17例，疗程2~9(6.1±1.97)年。两组在年龄、性别、BMI、NAs治疗时间及HBsAg水平方面差异均无统计学意义(P值均＞0.05)(表 1)。

表 1 基线时两组患者的临床资料对比

组别	例数	年龄 (岁)	男性 [例(%)]	BMI (kg/m²)	NAs治疗时间 (年)	HBsAg (log₁₀ IU/ml)
总体	42	47.43±7.10	35(83.33)	25.20±3.01	5.91±3.17	2.12±0.93
A组	22	44.82±6.20	19(86.36)	24.69±3.33	5.72±4.00	2.02±1.06
B组	20	47.70±5.11	16(80.00)	25.39±2.66	6.10±1.97	2.23±0.78
统计值		t=-1.634		t=-0.746	t=-0.388	t=-0.744
P值		0.110	0.691	0.460	0.701	0.462

下载: 导出CSV

| 显示表格

2.2 两组治疗24周和48周疗效比较

24周时A组的HBsAg清除率和HBsAg血清学转换率高于B组(P值均＜0.05)；48周时A组的HBsAg清除率达45.5%(10/22)，HBsAg血清学转换率达到31.8%(7/22)，均明显高于B组(P值均＜0.01)(表 2)。

表 2 两组不同时间节点临床治愈结果比较

组别	例数	24周		48周
组别	例数	HBsAg清除[例(%)]	抗-HBs阳性[例(%)]	HBsAg清除[例(%)]	抗-HBs阳性[例(%)]
A组	22	6(27.3)	5(22.7)	10(45.5)	7(31.8)
B组	20	0	0	0	0
P值		0.022	0.049	0.001	0.009

下载: 导出CSV

| 显示表格

2.3 影响48周HBsAg清除的基线因素分析

对可能影响HBsAg清除的因素进行多因素logsitic回归分析，结果显示：性别、BMI、ALT或AST升高以及NAs治疗时长均对HBsAg清除均无明显影响(P值均＞0.05);既往应用不同抗病毒药物LAM/ADV或ETV/TDF均对HBsAg清除无明显影响(P值均＞0.05)。开始联合治疗时的年龄对HBsAg清除存在影响[OR(95%CI)=0.877(0.781~0.985)，P=0.026]，HBsAg阴转患者的年龄集中在36~49(44.20±4.49)岁；基线HBsAg水平也对HBsAg清除存在影响[OR(95%CI)=0.996(0.992~1.000)，P=0.050)。

2.4 HBsAg亚组分析与HBsAg清除

本研究以不同节点及不同区间的HBsAg水平来划分联合治疗患者以更好的观察HBsAg清除率。48周“节点水平”的HBsAg检测值虽可对HBsAg清除有效预测，但该方法包括了重叠人群。再以“区间水平”对人群进行分段观察，HBsAg水平500~1000 IU/ml、100~500 IU/ml、10~100 IU/ml、＜10 IU/ml人群治疗48周时，HBsAg清除率分别为33.3%、50%、40%和100%(表 3、4)。

表 3 联合治疗基线值不同HBsAg定量节点的患者在12、24和48周获得临床治愈率比较

HBsAg节点	例数	12周治愈率	24周治愈率	48周治愈率
＜1000 IU/ml	19	26.3%(5/19)	31.6%(6/19)	52.6%(10/19)
＜500 IU/ml	13	38.5%(5/13)	46.2%(6/13)	61.5%(8/13)
＜100 IU/ml	9	55.6%(5/9)	55.6%(5/9)	66.7%(6/9)
＜10 IU/ml	4	100%(4/4)	100%(4/4)	100%(4/4)

下载: 导出CSV

| 显示表格

表 4 联合治疗基线值不同HBsAg定量区间的患者在12、24和48周获得临床治愈率比较

HBsAg区间	例数	12周治愈率	24周治愈率	48周治愈率
500~1000 IU/ml	6	0(0/6)	0(0/6)	33.3%(2/6)
100~500 IU/ml	4	0(0/4)	25.0%(1/4)	50.0%(2/4)
10~100 IU/ml	5	20.0%(1/5)	20.0%(1/5)	40.0%(2/5)
＜10 IU/ml	4	100%(4/4)	100%(4/4)	100%(4/4)

下载: 导出CSV

| 显示表格

2.5 更短疗程获得临床治愈

基线HBsAg＜10 IU/ml患者共4例，均于联合治疗12周取得临床治愈，巩固至24周，停药后抗-HBs持续升高，观察至48周均达到稳定阈值(抗-HBs＞100 IU/ml)，其中2例超过1000 IU/ml。

2.6 不良反应监测

在NAs联合PEG-IFN治疗期间，15例(15/24, 62.5%)于治疗早期出现发热，治疗过程中有10例(10/24, 41.7%)出现乏力症状，7例(7/24, 29.2%)出现食欲下降，4例(4/24, 16.7%)出现脱发现象。治疗过程中大多数患者都有WBC、PLT下降，给予对症治疗均能很快恢复正常。未见明显骨髓抑制、精神异常、自身免疫性疾病等严重不良反应。

3. 讨论

目前国内外有关乙型肝炎防治指南均较关注CHB的临床治愈问题，并强调在CHB的治疗和管理过程中，对于部分适合的患者，应尽可能追求临床治愈。针对HBeAg阴性CHB的抗病毒治疗, 采用NAs单药或IFN单药固定疗程(48周)的方法获得的HBsAg清除率极低^[7-8]；IFN能够增强HBV特异性细胞毒性T淋巴细胞的功能，又可以通过其受体经信号转导等生物化学过程启动多种抗病毒蛋白的合成，对HBV的复制和转录产生抑制，达到抗病毒及免疫调节的双重作用^[9-10]。NAs主要是通过竞争性抑制HBVDNA多聚酶及反转录酶直接抑制病毒复制，并可直接增强PEG-IFN诱导的固有免疫激活效应^[11]。联合两类不同作用机制的抗病毒药物治疗CHB可能存在协同作用，为快速实现临床治愈奠定理论基础^[12]。

本研究选取NAs经治48周以上HBeAg阴性、HBsAg＜1500 IU/ml的CHB患者，在NAs治疗基础上联合PEG-IFN治疗48周，与NAs单药组作对比，联合治疗组HBsAg清除率达到45.5%，HBsAg血清学转换率达到31.8%，NAs单药组无1例HBsAg清除，差异具有显著性。说明选取NAs经治的HBeAg阴性的CHB患者，给予积极联合PEG-IFN治疗，可以获得更高的临床治愈率。本研究治愈率较高与更多的患者HBsAg＜1000 IU/ml有关(19/22)，结果与宁琴主持OSST研究^[13]和任红主持New Switch研究^[14]一致。HBsAg清除的多因素logsitic回归结果显示，性别、BMI、ALT或AST升高、NAs治疗时长、既往应用不同抗病毒药物LAM/ADV或ETV/TDF均对HBsAg清除无明显影响(P值均＞0.05)。开始联合治疗时的年龄＜45岁，基线HBsAg水平＜500 lU/ml临床治愈率高。提示开始联合治疗时的年龄越低、HBsAg水平越低，更容易获得HBsAg清除。原因可能是中青年人群，新陈代谢机能旺盛，免疫功能良好，对PEG-IFN应答率高；在长期使用NAs治疗，对HBV DNA控制良好情况下，T淋巴细胞和NK细胞的特异性免疫应答功能得以恢复，也能够提高患者对PEG-IFN的应答率^[15-16]。很多研究已表明，基线HBsAg水平与HBsAg清除密切相关，基线水平越低，HBsAg清除率越高^[10]。

本研究HBsAg＜500 IU/ml水平的患者获得约61.5%的临床治愈率，HBsAg在500~1000 IU/ml、100~500 IU/ml、10~100 IU/ml及＜10 IU/ml人群的HBsAg清除率分别为33.3%、50.0%、40.0%和100%。陈新月研究团队^[17]对HBsAg低水平的HBeAg阴性CHB获得临床治愈优势人群的研究，采用“区间水平”划分人群，联合治疗48周100 IU/ml＜HBsAg＜1000 IU/ml、10 IU/ml＜HBsAg＜100 IU/ml以及HBsAg＜10 IU/ml人群的HBsAg清除率分别为6.7%、31.8%和67.7%。本研究结果与其相似，但本研究中HBsAg越低越容易获得临床治愈，更高的HBsAg清除率是在HBsAg＜10 IU/ml人群，且获得HBsAg血清学转换。说明基线HBsAg水平越低，获得临床治愈的联合治疗时间越短，与既往NAs用药时间长短无关。

本研究观察到联合治疗组在应用IFN早期会出现发热现象，部分患者治疗过程中出现乏力、食欲下降、脱发等临床表现，大多数患者有WBC、PLT水平下降情况，给予对症治疗均能很快恢复正常。未见明显骨髓抑制、精神异常、自身免疫性疾病等严重不良反应。联合用药的患者对于IFN的相关不良反应大多能够承受，为赢得临床治愈创造了机会。尽管本研究样本量较少，但优化出的无论哪种核苷类似物，基线HBsAg低水平(＜500 IU/ml)时加用PEG-IFN联合治疗24~48周，能够获得约61.5%的临床治愈率对基层临床医生具有重要的指导意义。

References(20)

References

[1] SHIRATA C,HASEGAWA K,KOKUDO T,et al. Liver resection for hepatocellular carcinoma in patients with renal dysfunction[J]. World J Surg,2018,42(12):4054-4062.

[2] ABOU-ALFA GK,MEYER T,CHENG AL,et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med,2018,379(1):54-63.

[3] GARDINI AC,FOSCHI FG,CONTI F,et al. Immune inflammation indicators and ALBI score to predict occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J]. Dig Liver Dis,2018,50(1):50-51.

[4] WANG M,XI D,NING Q. Virus-induced hepatocellular carcinoma with special emphasis on HBV[J]. Hepatol Int,2017,11(2):171-180.

[5] GAO Q,WANG K,CHEN K,et al. HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma.[J]. Cancer Sci,2017,108(7):1328-1337.

[6] SHI T,HUA Q,MA Z,et al. Downregulation of miR-200a-3p induced by hepatitis B virus X(HBx)protein promotes cell proliferation and invasion in HBV-infection-associated hepatocarcinoma[J]. Pathol Res Pract,2017,213(12):1464-1469.

[7] HUANG CF,HUANG CY,YEH ML,et al. Genetics variants and serum levels of MHC class I chain-related a in predicting hepatocellular carcinoma development in chronic hepatitis C patients post antiviral treatment[J]. Ebiomedicine,2017,15:81-89.

[8] HUANG CF,WANG SC,YEH ML,et al. Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication[J]. J Gastroenterol Hepatol,2019,34(1):249-255.

[9] SUN D,WANG X,ZHANG H,et al. MMP9 mediates MICA shedding in human osteosarcomas[J]. Cell Biol Int,2011,35(6):569-574.

[10] HEIMBACH JK,KULIK LM,FINN RS,et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2018,67(1):358-380.

[11] Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J]. Cell,2017,169(7):1327-1341. e23.

[12] QIN G,DANG M,GAO H,et al. Deciphering the proteinprotein interaction network regulating hepatocellular carcinoma metastasis[J]. Biochim Biophys Acta Proteins Proteom,2017,1865(9):1114-1122.

[13] CHEUNG KS,SETO WK,WONG DK,et al. Relationship between HBsAg,HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy[J]. J Viral Hepat,2017,24(8):654-661.

[14] WANG X,OISHI N,SHIMAKAMI T,et al. Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B[J]. World J Gastroenterol,2017,23(18):3252-3261.

[15] YANG Q,LI XP,ZHONG YB,et al. Interferon-αinhibits cell migration and invasion and induces the expression of antiviral proteins in Huh-7 cells transfected with hepatitis B virus X gene-expressing lentivirus[J]. Exp Ther Med,2017,14(6):5924-5930.

[16] BRABLETZ T,KALLURI R,NIETO MA,et al. EMT in cancer[J]. Nat Rev Cancer,2018,18(2):128-134.

[17] SABA NF,WANG Y,FU H,et al. Association of cytoplasmic CXCR4 with loss of epithelial marker and activation of ERK1/2and AKT signaling pathways in non-small-cell lung cancer[J]. Clin Lung Cancer,2017,18(3):e203-e210.

[18] HAI H,TAMORI A,THUY L,et al. Polymorphisms in MICA,but not in DEPDC5,HCP5 or PNPLA3,are associated with chronic hepatitis C-related hepatocellular carcinoma[J]. Sci Rep,2017,7(1):11912.

[19] ARAI J,GOTO K,STEPHANOU A,et al. Predominance of regorafenib over sorafenib:Restoration of membrane-bound MICA in hepatocellular carcinoma cells[J]. J Gastroenterol Hepatol,2018,33(5):1075-1081.

[20] CHEN J,XU H,ZHU XX. Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer[J]. Ther Clin Risk Manag,2016,12:11-18.

Relative Articles

[1]	Tong LIU, Shanzheng LI, Cheng ZHOU, Sutong LIU, Lihui ZHANG, Wenxia ZHAO. Study on the protective efect and mechanism of paeoniflorin on palmitic acid-induced HepG2 cells[J]. Journal of Clinical Hepatology, 2025, 41(3): 499-505. doi: 10.12449/JCH250316
[2]	Lai Xin, Zhou TaiCheng, Wei Jia. Association between HBV A1762T/G1764A double nucleotide substitution and liver diseases[J]. Journal of Clinical Hepatology, 2018, 34(9): 1990-1994. doi: 10.3969/j.issn.1001-5256.2018.09.034
[3]	Pang Ting, Xing HuiChun. Correlation between drug-resistance gene mutations and hepatocellular carcinoma in patients with hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2017, 33(1): 82-86. doi: 10.3969/j.issn.1001-5256.2017.01.017
[4]	Du SenRong, Mao XiaoRong, Xiao Ping, Chen Hong. Effects of PARP-1 inhibitors AG-014699 and AZD2281 on proliferation and apoptosis of human hepatoma cell line HepG2[J]. Journal of Clinical Hepatology, 2015, 31(6): 943-946. doi: 10.3969/j.issn.1001-5256.2015.06.027
[5]	Wang LiPing, Han FangZheng, Li ChunYang, Yan Mei, Zhang YanChao, Yan XueBing. Evaluation of adefovir primary resistance and adefovir repulsive mutations of the HBV DNA P gene in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(8): 606-608.
[6]	Jin WenWen, Xin YongNing, Dong QuanJiang, Zhao ShouFeng, Yu XinJuan, Jiang Man, Xu Jing, Xuan ShiYing. The preliminary study on the relationship between hepatitis B virus BCP gene mutations and HBV-related primary hepatocellular carcinoma in Qingdao[J]. Journal of Clinical Hepatology, 2012, 28(2): 130-134.
[7]	Yang YanLin, Xiao Ping, Gao Peng, Wang LiMing, Wei XiSheng, He Qiang, Zhou Ping. Distribution of HBV genotypes and YMDD mutations in E antigen-positive patients[J]. Journal of Clinical Hepatology, 2012, 28(6): 428-430.
[8]	Hong YuBo, Zhang Ting, Sun LiGuang. Association between IL-2 +114 (G/T) polymorphism and susceptibility to hepatitis B, cirrhosis, and hepatocellular carcinoma in Jilin province[J]. Journal of Clinical Hepatology, 2012, 28(12): 930-933.
[9]	Deng Le, Wen ZhiLi. Review of recent research progress in correlating HBV genotypes with efficacy of antiviral treatments[J]. Journal of Clinical Hepatology, 2012, 28(6): 469-473.
[10]	Zhang JianJun, Wu LiPing, Du RuiQing, Wang JianBin, Yao ZhanCheng, Yu GuiQin. Factors correlating with the liver inflammation grade ≥G2 in chronic HBV-infected patients with normal liver function[J]. Journal of Clinical Hepatology, 2012, 28(1): 35-38.
[11]	Liu JinPing, Liu YouDe, Guo YanMei, Yang ShaoPing, Lin Qing, Lin Ling. Clinical characteristics and distribution of hepatitis B virus genotypes in CHB patients in Yantai area[J]. Journal of Clinical Hepatology, 2011, 27(12): 1288-1290.
[12]	Zou XiaoJing, Jiang XueQiang, Tian DeYing. Role of DC-SIGN on the maturation and activation of dendritic cells in chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2011, 27(2): 145-147+153.
[13]	Xiong QiXiang, Xiong LiJuan. Hepatitis B virus infection and DNA methylation in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(8): 881-884.
[14]	Pan Lei, Wei Xin, Xie YuMei, Hao ChunQiu, Wang JiuPing, Jia ZhanSheng, Bai XueFan. Anti-viral therapy with pegylated interferon alpha-2a plus ribavirin in patients co-infected with HBV and HCV[J]. Journal of Clinical Hepatology, 2011, 27(1): 84-85+95.
[15]	Yuan JianGuo, Wang XinGuo, Cui Xia, Liu FengHua, Wang FengHua, Song JiKui, Zhao HongKui. The activation of rat hepatic stellate cells stimulated with hepatitis B virus in vitro[J]. Journal of Clinical Hepatology, 2011, 27(2): 163-165.
[16]	Xi HongLi, Liu FangFang, Yuan JiaYing, Yu YanYan. Significance and detection of IL-2、IL-4 and IFN-γ in PBMC from patients with hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2010, 26(6): 627-629.
[17]	Wang GuoQiang, Niu JuXia. The HBx protein mutation among different HBV genotypes[J]. Journal of Clinical Hepatology, 2010, 26(4): 392-394.
[18]	Shi YanMei, Lan YingHua, Dan Lei, Zhou Jin, Li YongGuo. The relationship between of hematopoietic stem cells and hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2010, 26(4): 377-380.
[19]	Xie DeSheng, Zhang QingBo, Chen ChangXing, Huang JianFang, Ma Jin, Huang HaiBin, Du Yao. The relationship between HBV gene mutation in HBV infected family and HLA class Ⅱ alleles[J]. Journal of Clinical Hepatology, 2010, 26(4): 383-386.
[20]	Xu ZhengJu, Yang Hong, Zhang QiHua, Chen XianLi, Li ShuQing, Wang ChongGuo. Study on the relationship between hepatitis B virus genotypes and effect of lamivudine therapy.[J]. Journal of Clinical Hepatology, 2005, 21(3): 157-159.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	刘华梅，孙家敏. 核苷（酸）类似物联合Peg-IFNα-2b治疗HBsAg低表达型慢性乙型肝炎临床效果. 中国现代医药杂志. 2024(05): 57-59 .
2.	李瑾，董京涛，董振博，张云，李志媛，王洁莹. 聚乙二醇干扰素α-2a联合恩替卡韦对慢性乙型肝炎患者相关指标的影响. 实用临床医药杂志. 2023(02): 92-96 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1303) PDF downloads(225)

Effect of hepatitis B x gene on the expression of major histocompatibility complex class I chain-related gene A-A5. 1,invasion,and migration of HepG2. 2. 15 cells

DOI: 10.3969/j.issn.1001-5256.2020.04.020